Results 251 to 260 of about 470,839 (363)

Angiotensin-converting enzyme genotypes and sarcoidosis: Correlation with susceptibility, progression and treatment response. [PDF]

open access: yesSarcoidosis Vasc Diffuse Lung Dis
Møller J   +4 more
europepmc   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

open access: yesESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori   +9 more
wiley   +1 more source

Angiotensin-converting enzyme inhibitors for aortic stenosis: a drug-target Mendelian randomization study. [PDF]

open access: yesInt J Cardiol Heart Vasc
Ciofani JL   +5 more
europepmc   +1 more source

Angiotensin-converting enzyme inhibitors for ovarian cancer? — a new adjuvant option or a silent trap

open access: diamond, 2023
Katarzyna Regulska   +5 more
openalex   +2 more sources

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

open access: yesESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage   +23 more
wiley   +1 more source

Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic score. [PDF]

open access: yesWorld Allergy Organ J
Bocquet A   +3 more
europepmc   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy